从诊断不确定性到向治疗:基于VEXAS综合征的病例审查
Gunjan Rana1, Garima Singh2, Mansi Mehta3
1Department of Internal Medicine, Saint Vincent Hospital, Worcester, MA, USA. ranagunjanrana@gmail.com.
Rheumatology international
|September 4, 2025
概括
这是一种体质的UBA1突变疾病,表现为严重的炎症和血液问题. 针对IL-1和IL-6的生物疗法在治疗症状和减少类固醇依赖方面表现有前途.
科学领域:
- 遗传学和免疫学
- 在UBA1基因的体质突变
- 自炎症性疾病
背景情况:
- 维克萨斯综合征 (空腔,E1酶,X链,自身炎症,体质) 是最近发现的一种自身炎症性疾病.
- 由体质UBA1突变引起的,它表现为难以治疗的全身炎症和血液异常.
- 诊断延迟和有限的治疗共识使临床管理复杂化.
研究的目的:
- 为了说明VEXAS综合征患者的表型异质性和治疗反应.
- 对VEXAS综合征的治疗结果进行文献审查.
- 突出VEXAS综合征管理中的诊断和治疗挑战.
主要方法:
- 两名经遗传确认的VEXAS综合征成年男性的案例研究.
- 通过下一代测序检测体质UBA1突变证实了诊断.
- 在2024年10月之前对VEXAS综合征治疗结果的叙述文献综述.
主要成果:
- 这两位患者都出现了VEXAS的典型特征:多系统炎症和细胞衰竭.
- 基因测序证实了体质的UBA1突变.
- 皮质类固醇与生物药物 (托西利祖马布,卡纳基努马布) 结合使用可实现临床稳定和降低类固醇剂量.
结论:
- 诊断VEXAS综合征需要高度怀疑和基因检测.
- 针对IL-1和IL-6途径的生物疗法提供了潜在的类固醇节约选择.
- 需要进一步的前性研究来确定VEXAS综合征的最佳治疗策略.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Appendicitis-II: Diagnostic Studies and Management
143
Diagnosing and managing appendicitis requires a structured and comprehensive approach that spans from initial assessment to postoperative care. Here is an overview of the process:
Diagnosing Appendicitis
It requires a multifaceted approach, starting with a detailed physical examination to pinpoint the location and nature of the pain and identify any associated symptoms. Laboratory tests play a crucial role. A complete Blood Count (CBC) typically reveals leukocytosis (an increased number of...
Diagnosing Appendicitis
It requires a multifaceted approach, starting with a detailed physical examination to pinpoint the location and nature of the pain and identify any associated symptoms. Laboratory tests play a crucial role. A complete Blood Count (CBC) typically reveals leukocytosis (an increased number of...
143
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
232
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
232
Acute Pyelonephritis II: Diagnostic Studies and Management
38
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
38


